Skip to main content

Innovations to Address Global Drug Counterfeiting: Implications for Urbanization and Health

  • Chapter

Abstract

The recent rise in counterfeits has now extended from basic consumer goods and electronics to pharmaceuticals, jeopardizing the health of millions across the globe.

Estimates suggest that the counterfeit industry is now $75 billion and will grow by 20 % per year, making it one of the fastest growing public health risks [Poison pills. The Economist. 2012]. Counterfeit medications, comprising more than 30 % of medications in parts of Asia, Africa, and Latin America, have only recently gained recognition by the general public and mainstream media. Although the burden of disease lies largely with the world’s most vulnerable populations, Western countries are not insulated from this problem [The deadly world of fake drugs, Washington, DC]. With the rapid growth of online pharmacies, the currently quoted 1 % prevalence of counterfeit medications in the United States will quickly rise [World Health Organization, IMPACT. Counterfeit drugs kill! 2008]. The Internet, which boasts up to 50 % prevalence of counterfeit pharmaceuticals, has introduced medications such as blood pressure control, lifestyle medications, and pain modulators to the list of counterfeited medications.

The traditional definition of counterfeit medications, including both generic and brand name, is medications deliberately and fraudulently mislabeled with respect to identity and/or source [Counterfeit medical products: report by the secretariat. Geneva]. In some instances, counterfeiting involves manufacturing a drug without its active ingredient—with chalk, starch, flour, or talcum powder in place of any active compound. Although less harmful than some of the more menacing manufacturing techniques, this approach puts patients at risk of morbidity and mortality from otherwise treatable diseases. In a more sinister approach, these formulations can be made with substitute medications providing relief of symptoms but not treatment of disease, for example, filling an antimalarial with acetaminophen, which will lower the fever of malaria but will not treat the underlying parasite. Other medications may have active ingredients but at nontherapeutic doses. This “up marketing” of medications runs the risk of creating resistance in the partially treated host. These substandard medications subject patients to treatment failures and create drug-resistant organisms. Lastly, and perhaps the most publicized aspect of this issue, is the inclusion of noxious chemicals in medications marketed as therapeutic pharmaceuticals. Most notoriously, in place of the glycerin normally used in cough syrup, the toxic substance diethylene glycol has been used because of its similar taste, color, consistency, and lower cost.

Counterfeit pharmaceuticals thus have significant public health consequences beyond their individual-level effects. These falsified medications jeopardize the primary care environment by undermining people’s faith in their physicians and making them question the integrity of the pharmaceutical supply chain.

This chapter will provide an overview of drug counterfeiting globally, describe its potential impact for urbanization and health, and discuss various mechanisms to address this problem.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Poison pills. The Economist. September 2, 2012; print edition.

    Google Scholar 

  2. Putze E, Conway E, Reilly M, Madrid O. The deadly world of fake drugs. Washington, DC: AEI; 2012.

    Google Scholar 

  3. World Health Organization, IMPACT. Counterfeit drugs kill! 2008.

    Google Scholar 

  4. Board WHOE, editor. Counterfeit medical products: report by the secretariat. Geneva: World Health Assembly; 2008.

    Google Scholar 

  5. Bogdanich W, Hooker J. From China to Panama, a trail of poisoned medicine. New York Times. 2007.

    Google Scholar 

  6. Bogdanich W. F.D.A. tracked poisoned drugs, but trail went cold in China—New York Times. New York Times. 2007.

    Google Scholar 

  7. World Health Organization (WHO) | Counterfeit medicines. Fact sheet. WHO. 2006.

    Google Scholar 

  8. Mackey TK, Liang BA. The global counterfeit drug trade: patient safety and public health risks. J Pharm Sci. 2011;100:4571–9.

    Article  CAS  PubMed  Google Scholar 

  9. Clift C. Combating counterfeit, falsified and substandard medicines: defining the way forward? London: Chatham House; 2010.

    Google Scholar 

  10. International Narcotics Control Board, INCB. INCB warns of counterfeit medicines flooding markets. Press release, 2 Mar 2007.

    Google Scholar 

  11. Finlay BD. Counterfeit drugs and national security. Stimson Center, Washington D.C. Feb. 2011.

    Google Scholar 

  12. Pharmaceutical Security Institute. Incident Trends. 2012. http://www.psi-inc.org/incidentTrends.cfm. Accessed 24 Mar 2012.

  13. IMPACT. Third IMPACT general meeting, 3-5 September 2008, Hammamet, Tunisia, Summary Report.

    Google Scholar 

  14. Clift C. Combating counterfeit, falsified and substandard medicines: defining the way forward? Center on Global Health Security, Chatham House. Chatham House Briefing Paper. November 2010.

    Google Scholar 

  15. World Health Organization. General information on counterfeit medicines. World Health Organization website. 2010.

    Google Scholar 

  16. Harper DE. EU customs blockade of India’s generic medicines. The Student Appeal. 2011.

    Google Scholar 

  17. Newton PN, Green MD, Fernández FM, Day NP, White NJ. Counterfeit anti-infective drugs. Lancet Infect Dis. 2006;6:602–13.

    Article  CAS  PubMed  Google Scholar 

  18. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005;2:e100.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Council of Europe. Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health. Council of Europe. 2012.

    Google Scholar 

  20. Health ECP, Editor. Pharmacovigilance—major developments. 2012. http://www.pharmacovigilance2012.nl/2012/06/21/adoption-and-publication-of-commission-implementing-regulation/.

  21. Amending Directive 2001/83/EC on the community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products. Directive of the European Parliament and of the Council. Official Journal of the European Union. July 1, 2011.

    Google Scholar 

  22. World Health Organization. Medicines: spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines. Fact Sheet No. 75. May 2012. http://www.who.int/mediacentre/factsheets/fs275/en/index.html

  23. Verified Internet Pharmacy Practice Sites (VIPPS). The National Association of Boards of Pharmacy (NABP). 2012. http://vipps.nabp.net

  24. US Food and Drug Administration. Pathway to global product safety and quality. US Food and Drug Administration. July 7, 2011.

    Google Scholar 

  25. US Food and Drug Administration. Prescription drug marketing act of 1987. US Food and Drug Administration website. 2012.

    Google Scholar 

  26. Commissioner OOT. US Food and Drug Administration. Drug safety and availability—FDA initiative to combat counterfeit drugs. US Food and Drug Administration website. 2009.

    Google Scholar 

  27. International Federation of Pharmaceutical Manufacturers & Associations. Counterfeit: IFPMA. International Federation of Pharmaceutical Manufacturers & Associations. 2012. http://www.ifpma.org/global-health/counterfeits.html

  28. World Health Organization Western Pacific Region (WPRO). Rapid Alert System for combating counterfeit medicine. WPRO. 2012.

    Google Scholar 

  29. Hellerman C. FDA commissioner talks counterfeit drugs. CNN. 2012.

    Google Scholar 

  30. H.R.3368. - Counterfeit drug penalty enhancement act of 2011. 112th Congress (2011–2012).

    Google Scholar 

  31. PhRMA. Counterfeit drug penalty enhancement act of 2011 can help crack down on counterfeiting crimes. PhRMA. Press release, November 17, 2011.

    Google Scholar 

  32. Green MD. Antimalarial drug resistance and the importance of drug quality monitoring. J Postgrad Med. 2006;52:288–90.

    CAS  PubMed  Google Scholar 

  33. Hearing on H.R. 4223, the “Safe Doses Act”; H.R. 3668, the “Counterfeit Drug Penalty Enhancement Act of 2011”; and H.R 4216, the “Foreign Counterfeit Prevention Act”. Subcommittee on Crime, Terrorism, and Homeland Security, Committee on the Judiciary. 2012.

    Google Scholar 

  34. Interpol. Training and operational workshops build capacity to fight counterfeit goods affecting consumer safety throughout Western and Northern Africa. Press Release, 21 May 2010.

    Google Scholar 

  35. Sanofi-Aventis. Press pack: Drug counterfeiting. Sanofi fights against counterfeit medicines. Sanofi-Aventis. 2012.

    Google Scholar 

  36. Abdoulaye I, Chastanier H, Azondekon A, Dansou A, Bruneton C. [Survey on the illicit drug market in Cotonou, Benin in March 2003]. Med Trop (Mars). 2006;66:573–6.

    CAS  Google Scholar 

  37. Fahelelbom KMS, Al-Zubiadi T, Abdulah A, Talal A. Drug counterfeiting problems (Survey study on public awareness of drug counterfeiting in UAE and Tunisia). In: 11th sci conference for Arab Pharm Colleges. Tripoli, Libya. 2007.

    Google Scholar 

  38. Abdoulaye I, Chastanier H, Azondekon A, Dansou A, Bruneton C. Evaluation of public awareness campaigns on counterfeit medicines in Cotonou, Benin. Med Trop (Mars). 2006;66:615–8.

    CAS  Google Scholar 

  39. Cuchet-Chosseler M, Bocoum O, Camara M, Abad B, Yamani E, Ordre PM. Results of a survey to evaluate the efficacy of a regional awareness campaign on counterfeit street medicines in Bamako, Mali and Nouakchott, Mauritania. Med Trop (Mars). 2011;71:152–6.

    CAS  Google Scholar 

  40. World Anti Counterfeiting Day 2012. 2012. http://www.gacg.org/News/Read/53. Accessed 12 July 2012.

  41. Inksure Technologies Inc. http://www.inksure.com/pharmaceutical-anti-counterfeiting. Inksure Technologies Inc. website. Accessed 12 July 2012.

  42. The Partnership for Safe Medicines. Moving past the Avastatin incident: PSM counterfeit drug congressional briefing held on March 15. Partnership for Safe Medicines website. http://www.safemedicines.org/2012/03/psm-to-conduct-counterfeit-drug-congressional-briefing-on-march-8-.html. Accessed 9 July 2012.

  43. Sharma Y. Fighting fake drugs with high-tech solutions. SciDevNet. 2011. http://www.scidev.net/en/features/fighting-fake-drugs-with-high-tech-solutions-1.html. Accessed 6 July 2012.

  44. Dialing for development: how mobile phones are transforming the lives of millions. WIPO Magazine. 2010.

    Google Scholar 

  45. http://counterfeitdrugs.wordpress.com/videos/. Counterfeit Drugs Around the World website Accessed 24 Sept 2013.

  46. Pharmaceutical Security Institute. http://www.psi-inc.org/index.cfm. Pharmaceutical Security Institute website. Accessed 24 Sept 2013.

  47. 2012 Partnership for Safe Medicines Interchange. http://www.safemedicines.org/counterfeit-drug-conference-2012.html. Accessed 9 July 2012.

  48. World Health Organization. Rapid Alert System for combating counterfeit medicine. World Health Organization. 2005.

    Google Scholar 

  49. IMPACT. Facts|Activities|Documents developed by the Assembly and the Working Groups of IMPACT 2006−2010. Agenzia Italiana del Farmaco. 2011.

    Google Scholar 

  50. Research B. Anti counterfeiting packaging technologies in the US Pharmaceutical and Food Industries. 2011.

    Google Scholar 

  51. Shah RY, Prajapati PN, Agrawal Y. Anticounterfeit packaging technologies. J Adv Pharm Technol Res. 2010;1:368.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Keynote presentations by Howard Zucker at (1) WHO IMPACT Technology Working Group: Prague, Czech Republic, 13 Mar 2007. (2) Using cell phones to improve health, GSM International Conference, Barcelona, Spain, 13 Feb 2007 and (3) Combating counterfeit drugs: building effective collaboration, International conference on combating counterfeit medicine, WHO—AIFA Conference, Rome, Italy, 17−20 Feb 2006.

    Google Scholar 

  53. Sproxil. The fight against counterfeit drugs continues. 2011. http://tech.233.com.gh/posts/2011/unwired/sproxil-fight-against-counterfeit-drugs-continues/.

  54. Eliminate counterfeit goods efficiently and effectively. http://www.protexxion.de/en/home.html. Accessed 9 July 2012.

  55. Mehta R. Biometric fingerprints for anti-counterfeiting. The Packaging Professional. 2007.

    Google Scholar 

  56. Bastia S. Next generation technologies to combat counterfeiting of electronic components. IEEE Trans Compon Packag Technol. 2002;25:175–6.

    Article  Google Scholar 

  57. Newton P, Proux S, Green M, et al. Fake artesunate in southeast Asia. Lancet. 2001;357:1948–50.

    Article  CAS  PubMed  Google Scholar 

  58. FDA warns consumers about counterfeit version of Teva’s Adderall. 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm305932.htm. Accessed 9 July 2012.

  59. Macleod NA, Matousek P. Emerging non-invasive Raman methods in process control and forensic applications. Pharm Res. 2008;25:2205–15.

    Article  CAS  PubMed  Google Scholar 

  60. Dunn JD, Gryniewicz-Ruzicka CM, Kauffman JF, Westenberger BJ, Buhse LF. Using a portable ion mobility spectrometer to screen dietary supplements for sibutramine. J Pharm Biomed Anal. 2011;54:469–74.

    Article  CAS  PubMed  Google Scholar 

  61. The GPHF-Minilab®—protection against counterfeit medicines. http://www.gphf.org/web/en/minilab/index.htm. Accessed 6 July 2012.

  62. Kwok S, Ting JSL, Tsang AHC, Lee W, Cheung BCF. Design and development of a mobile EPC-RFID-based self-validation system (MESS) for product authentication. Comput Ind. 2010;61:624–35.

    Article  Google Scholar 

  63. Choi S, Poon C. An RFID-based anti-counterfeiting system. IAENG Int J Comput Sci. 2008;35:80–91.

    Google Scholar 

  64. Coustasse A, Arvidson C, Rutsohn P. Pharmaceutical counterfeiting and the RFID technology intervention. J Hosp Mark Public Relations. 2010;20:100–15.

    Article  PubMed  Google Scholar 

  65. Guidance document on the use of detection technologies and overview of detection technologies for drug safety. APEC Life Science Innovation Forum Beijing, China. 2011.

    Google Scholar 

  66. Interpol. Global operation strikes at online supply of illegal and counterfeit medicines worldwide. Media release. September 29, 2011.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emily Aaronson M.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer New York

About this chapter

Cite this chapter

Amico, K., Aaronson, E., Zucker, H. (2015). Innovations to Address Global Drug Counterfeiting: Implications for Urbanization and Health. In: Ahn, R., Burke, T., McGahan, A. (eds) Innovating for Healthy Urbanization. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7597-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-7597-3_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-7596-6

  • Online ISBN: 978-1-4899-7597-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics